Cell News and Research

RSS

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

The Human Papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer, but is also associated with several other types of cancer.

12 Mar 2010

OXiGENE signs definitive agreement to sell Common Stock

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock in a private placement.

12 Mar 2010

Tel Aviv University investigates cause and effects of SCA syndrome

Sudden Cardiac Arrest syndrome (SCA) is poorly understood, but it's a real danger for the otherwise young and healthy. For no apparent reason, the heart suddenly stops beating, and without treatment death may follow within minutes. It's why some athletes drop dead on the track and why a young man, without any warning, suddenly dies while sitting at his desk.

11 Mar 2010

Researchers identify a novel source of adult stem cells: Foreign body-induced granulation tissue

In a pioneering new study published in the journal Translational Research, Dr. Jilpa Patel and her research group at Hektoen Institute of Medicine and Cook County Hospital in Chicago have isolated and characterized adult stem cells from granulation tissue in rats. A granulation tissue is a new regenerating tissue formed in response to an inert foreign body placed in the subcutaneous tissue.

11 Mar 2010

Pro-Pharmaceuticals announces closing of $335,000 tranche of private placement

Pro-Pharmaceuticals, Inc., today announced that it has closed a $335,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.1 million.

11 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).

11 Mar 2010

TTI granted exclusive worldwide rights to commercialize two immunology programs

Trillium Therapeutics Inc., a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into two definitive license agreements with University Health Network and The Hospital for Sick Children in Toronto, Ontario, granting Trillium exclusive worldwide rights to commercialize two immunology programs in the areas of hematopoietic stem cell transplantation and cancer.

11 Mar 2010

USPTO issues patent related to Seattle Genetics' ADC technology

Seattle Genetics, Inc. announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics’ ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators.

11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

Fewer injections to treat neutropenia in childhood cancer patients

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

11 Mar 2010

Investigators develop new mathematical approach to analyze molecular data

Investigators have developed a new mathematical approach to analyze molecular data derived from complex mixtures of immune cells. This approach, when combined with well-established techniques, readily identifies changes in small samples of human whole blood, and has the potential to distinguish between health and disease states.

11 Mar 2010

Genomatix systems utilized to analyze cis and epigenetic elements that control reproductive events

The C.S. Mott Center for Human Growth and Development, Department of Obstetrics and Gynecology, at the Wayne State University School of Medicine, in collaboration with the Center for Molecular Medicine and Genetics, the Karmanos Cancer Institute and the Institute for Environmental Health Sciences, installed a Genomatix Mining Station and a Genomatix Genome Analyzer last year at their labs in Detroit, MI in order to support the analysis of Next Generation Sequencing (NGS) data.

11 Mar 2010

Refining treatments to target only key heart-related mechanisms may improve effectiveness

Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effects. New basic science findings from a University of Iowa study suggest a way that treatments could potentially be refined so that they work better and target only key heart-related mechanisms.

11 Mar 2010

Study uncovers mechanism facilitating motivation for alcohol after extended abstinence

New research provides exciting insight into the molecular mechanisms associated with addiction and relapse. The study, published by Cell Press in the March 11 issue of the journal Neuron, uncovers a crucial mechanism that facilitates motivation for alcohol after extended abstinence and opens new avenues for potential therapeutic intervention.

11 Mar 2010

Great Point and Deerfield invest in BioSante Pharmaceuticals

BioSante Pharmaceuticals, Inc. today announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.4 million shares of BioSante’s common stock and warrants to purchase up to approximately 5.2 million shares of its common stock, resulting in gross cash proceeds to BioSante of $18 million.

11 Mar 2010

Controlling cholesterol using biologically active molecules isolated from algal infusion

Researchers at Wayne State University's Department of Nutrition and Food Science believe they've uncovered a unique method to control and regulate cholesterol using biologically active molecules isolated from ProAlgaZyme™ -- a proprietary algal infusion produced by Health Enhancement Products, Inc., of Scottsdale, Arizona.

11 Mar 2010

Octenol compound aids mosquitoes in finding blood meal

The potentially deadly yellow-fever-transmitting Aedes aegypti mosquito detects the specific chemical structure of a compound called octenol as one way to find a mammalian host for a blood meal, Agricultural Research Service (ARS) scientists report.

11 Mar 2010

Cell News and Research

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

OXiGENE signs definitive agreement to sell Common Stock

Tel Aviv University investigates cause and effects of SCA syndrome

Researchers identify a novel source of adult stem cells: Foreign body-induced granulation tissue

Pro-Pharmaceuticals announces closing of $335,000 tranche of private placement

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

TTI granted exclusive worldwide rights to commercialize two immunology programs

USPTO issues patent related to Seattle Genetics' ADC technology

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

Fewer injections to treat neutropenia in childhood cancer patients

Investigators develop new mathematical approach to analyze molecular data

Genomatix systems utilized to analyze cis and epigenetic elements that control reproductive events

Refining treatments to target only key heart-related mechanisms may improve effectiveness

Study uncovers mechanism facilitating motivation for alcohol after extended abstinence

Great Point and Deerfield invest in BioSante Pharmaceuticals

Controlling cholesterol using biologically active molecules isolated from algal infusion

Octenol compound aids mosquitoes in finding blood meal

Improve fermentation and cell culture performance with real-time gas analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo